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Supplementation of omega-3 fatty acids (Ω-3) has been associated with a decreased car-
diovascular risk, thereby concentrating attention on a potentially preventive effect regarding
tachyarrhythmias and sudden cardiac death. However, recent randomized controlled trials
challenge the efﬁcacy of the additional application ofΩ-3 and its anti-arrhythmic effect under
certain clinical conditions.The present paper reﬂects the results of earlier and recent clinical
studies with respect to the individual background conditions that may determine the clinical
outcome ofΩ-3 supplementation and thereby explain apparently conﬂicting clinical results.
It is concluded that the efﬁcacy of Ω-3 supplementation to prevent cardiac arrhythmias
strongly depends on the underlying clinical and pharmacological conditions, a hypothe-
sis that also is supported by data from experimental animal studies and by molecular
interactions of Ω-3 at the cellular level.
Keywords: omega-3 unsaturated fatty acids, arrhythmia, prevention, cardiovascular disease, myocardial infarction,
death, sudden
INTRODUCTION
It is a great desire of humans to ﬁnd golden ways to solve major
problems, especially to treat severe diseases effectively in order to
prolong life,whenever possiblewithout creating additional risks or
side effects. In the past, omega-3 polyunsaturated fatty acids (Ω-
3), especially eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), appeared to be compounds having the potential to
fulﬁll this dream, if supplemented to daily nutrition in sufﬁcient
amounts.
Consequently, a huge amount of data has been accumulated
on this topic and many reviews and meta-analyses have been pub-
lished (Bucher et al., 2002; Leaf et al., 2003; Whelton et al., 2004;
Yzebe and Lievre, 2004; Dhein et al., 2005; Hooper et al., 2006;
Reiffel and McDonald, 2006;Wang et al., 2006; Lombardi and Ter-
ranova, 2007; Cheng and Santoni, 2008; Jenkins et al., 2008a; León
et al., 2008; Siddiqui et al., 2008; Marik and Varon, 2009; Zhao
et al., 2009; Filion et al., 2010; Mozaffarian et al., 2011a).
Based on this background the purpose of the present paper is
not to again review all the available data on Ω-3 effects or to dis-
cuss omega-3 unsaturated fatty acids as essential compounds in
human and animal biology. This paper focuses on the effects of
supplementation with Ω-3 on cardiac rhythm and discusses the
potential clinical consequences of recent clinical studies that do
not support the existence of this “golden Ω-3 way”. Furthermore,
the complexity of the biological interactions of Ω-3 as well as
the variation of potential clinical settings are outlined in order to
explain that supplementation withΩ-3 does not necessarily result
in an overall beneﬁcial clinical effect in every condition.
EARLIER CLINICAL STUDIES
An inverse relationship between consumption of ﬁsh oil and car-
diovascular risk was shown in early observational, case–control,
and cohort studies, with respect to the occurrence of cardiovas-
cular disease (Whelton et al., 2004), sudden cardiac death (SCD)
and non-SCD from coronary heart disease (Daviglus et al., 1997),
and with regard to SCD in apparently healthy persons (Siscovick
et al., 1995; Albert et al., 1998, 2002; Hu et al., 2002; Mozaffarian
et al., 2003). Ω-3 levels in erythrocyte membranes were directly
associated with a reduced rate of primary cardiac arrest (Siscovick
et al., 1995). Similarly, elevated Ω-3 blood levels were associated
with a reduced risk of sudden death among men without evidence
of prior cardiovascular disease (Albert et al., 2002).
These data were supported by prospective and randomized
nutritional intervention studies of secondary prevention after
acute myocardial infarction (AMI). In the Diet and Reinfarction
Trial (DART) a diet rich in ﬁsh and cereals was associated with
a signiﬁcant 29% reduction of all-cause mortality within 2 years
after AMI (Burr et al., 1989). In the Lyon Diet Heart Study the
Mediterranean diet group [diet enriched by alpha-linolenic acid
(ALA, Ω-3) and olive oil, combined with an increased intake of
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cereals, fresh fruit, vegetables and ﬁsh, but limited intake of satu-
rated fatty acids and linoleic acid (Ω-6)] had a signiﬁcantly lower
rate of the combined endpoint cardiac death andnon fatalmyocar-
dial infarction, if compared to the control group taking a prudent
western-type diet (p = 0.0001; follow-up 27months; de Lorgeril
et al., 1994, 1998, 1999).
A predeﬁned supplementation with Ω-3 was used in the
large placebo-controlled, open labeled GISSI Prevenzione Trial
(EPA+DHA 1 g/day, vitamin E 300mg/day, a combination of
both, or placebo; GISSI-Prevenzione Investigators, 1999), focusing
on secondary prevention after AMI. In this study the intervention
arms using Ω-3 showed a signiﬁcant reduction of SCD – though
this was not the primary endpoint of the GISSI Prevenzione Trial.
ANIMAL STUDIES
In parallel to these encouraging clinical data, animal studies
(mostly using the rat or canine model) supported an anti-
arrhythmic effect of Ω-3 especially with respect to ischemia-
induced ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF) (Matthan et al., 2005;Billman,2006). The clearest effect in the
prevention ofVFbyΩ-3 could be shown in infusion studies using a
special experimental caninemodel. In thismodel acutemyocardial
ischemia was induced at a site distant from a previous myocar-
dial infarction during submaximal exercise thereby activating the
autonomic nervous system (Billman, 2006) and inducing VF.
However, these clear effects of Ω-3 under well-deﬁned exper-
imental conditions cannot simply be translated into the clinical
situation, and several aspects have to be considered (Billman,
2006):
a. In this canine model not only superfusion withΩ-3 but also the
application of β-receptor antagonists, calcium-channel block-
ers, and endurance exercise training – all interventions that are
routinely used in actual clinical practice – were effective in VF
prevention.
b. Not all dogs were susceptible to ischemia-induced VF in this
model. Animals resistant to VF were characterized by reduced
β-receptor responsiveness and an intact parasympathetic regu-
lation, indicating that these are ﬁrst line mechanisms to prevent
ischemia-induced tachyarrhythmias.
c. Finally, incorporation of Ω-3 into the phospholipid bilayer
can be expected to be signiﬁcantly less in infusion studies as
compared to feeding studies.
Feeding studies more closely may imitate the clinical situa-
tion, and under these conditions Ω-3 can be expected to exert
their effect primarily after being incorporated into the cellular
membrane.Numerous animal feeding studies have been published
between 1987 and 1999, and the results showed a considerable het-
erogeneity. Still, a meta-analysis of these studies suggests ﬁsh oil
does prevent ischemia and ischemia-reperfusion induced VT/VF
(Matthan et al., 2005).
Heterogeneity of experimental results also can be seen in
more recent studies. In isolated hearts of pigs fed with ﬁsh oil
for 8weeks, spontaneous ischemia-induced sustained VT/VF was
facilitated in the Ω-3 group (Coronel et al., 2007). Other studies
report increased resistance to ischemia-reperfusion injury after
dietary Ω-3 application, which also could be a basis to pro-
tect against reperfusion arrhythmias (Abdukeyum et al., 2008;
Zeghichi-Hamri et al., 2010).
RECENT CLINICAL STUDIES
The results of the animal studies and their apparent inconsistencies
may be remembered when judging the data of recent prospec-
tive, randomized, double-blind clinical studies that interrupted
the long list of positive results of older studies investigating the
effect ofΩ-3 on cardiovascular risk. In the following, these studies
and the potential clinical consequences will be discussed in more
detail.
1. Three randomized prospective studies evaluating the effect of
high doses of Ω-3 in patients with ICD-devices failed to give
homogeneous results.
In one study recurrent VT events not due to myocardial
ischemia were more common in patients treated with ﬁsh oil
(1.3 gΩ-3 per day during a period of two years; p < 0.007; Raitt
et al., 2005).
However, in another studypredominantly includingpatients
with coronary artery disease,Ω-3 supplementation was associ-
ated with a signiﬁcant risk reduction for the primary endpoint
(time to ﬁrst ICD-event or death from any cause) by 31%
(p = 0.033). The death rates did not signiﬁcantly differ between
the study groups. Remarkably in this study no signiﬁcant effect
of Ω-3 could be shown in the subgroups of patients with-
out coronary artery disease or with a left ventricular ejection
fraction above 30% (Leaf et al., 2005a).
Finally the SOFA-study did not show a signiﬁcant effect
of Ω-3 supplementation on the primary endpoint (appropri-
ate ICD-interventions for recurrent VT/VF or death from any
cause; hazard ratio 0.86, 95% CI 0.64–1.16). The majority of
the patients included in the SOFA-study had coronary artery
disease, more than 60% with previous myocardial infarction;
almost 40% of the study participants had various forms of
cardiomyopathy or valvular heart disease (Brouwer et al., 2006).
In a meta-analysis of these three studies all-cause mortality
did not signiﬁcantly differ between the ﬁsh oil and the con-
trol groups (relative risk 0.70; 95% CI 0.42–1.15; Jenkins et al.,
2008b).
Finally, in a substudy of the GISSI-HF trial (566 heart
failure patients with implanted ICD-devices, 57% with pre-
vious myocardial infarction, mean follow-up 928 days) a sta-
tistically non-signiﬁcant trend toward a lower risk of ICD-
discharge in patients treated with Ω-3 was shown [adjusted
hazard ratio (HR) 0.80; 95% CI 0.59–1.09; p = 0.152]. How-
ever, mortality was similar in both groups [total mortality:
Ω-3 (26.6%), placebo (24.3%); adjusted HR 1.25; 95% CI
0.89–1.75; p = 0.19; mortality for arrhythmias: Ω-3 (3.6%),
placebo (2.1%); adjusted HR 1.84; 95% CI 0.67–5.05; Finzi
et al., 2011]. Therefore the clinical signiﬁcance of these data
remains debatable.
The apparent heterogeneity in the response of ICD-patients
to ﬁsh oil supplementation could be a consequence of different
study populations and different arrhythmic origins (ischemic
versus non-ischemic). Heterogeneity also could be the result
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of different concomitant medications of the study popula-
tions including β-blockers, digoxin, amiodarone, and sotalol.
A potential inﬂuence of medication on the effect of ﬁsh oil
supplementation may be indicated by the results of the DART
2 study (Burr et al., 2003).
2. In the controlled prospective DART 2 trial conducted with
general practitioners of South Wales male patients with sta-
ble angina (n = 3,114, under 70 years of age) were randomly
allocated to four study groups with speciﬁc nutritional advises
including the advise to eat oily ﬁsh or take ﬁsh oil capsules in
twoof the study groups. Survivalwasmeasuredduring a follow-
up of 3–9 years. The risk of SCD was signiﬁcantly increased in
the group taking oily ﬁsh or ﬁsh oil capsules (HR 1.54; 95% CI
1.06–2.23; Burr et al., 2003). The adverse effects of ﬁsh or ﬁsh
oil capsules only occurred in men not taking beta-blockers or
dihydropyridine calcium-channel blockers, and were increased
in patients taking digoxin (Burr et al., 2005). Unfortunately, a
conclusive interpretation of the DART 2 data is seriously lim-
ited as patient’s recruitment and monitoring was interrupted
for 1 year, long-term compliance was uncertain, and sudden
death could not be ascertained in all cases (Burr et al., 2003).
3. In the large scale multicenter Japan EPA Lipid Intervention
Study (JELIS; Yokoyama et al., 2007) consumption of 1.8 g
EPA per day over a mean period of 4.6 years in hyperlipidemic
patients (noAMI in the last 6months, no serious heart disease)
treated with statins resulted in a reduction of major cardio-
vascular events (combined endpoint including SCD, fatal and
non-fatal myocardial infarction, and other non-fatal events
including unstable angina, angioplasty, stenting, or coronary
bypass grafting) from 3.5 to 2.8% (p = 0.011; HR 0.81; 95%
CI 0.69–0.95). However, there was neither a reduction of SCD
(0.2% in both study arms; HR 1.06; 95% CI 0.55–20.07) nor
of coronary death (0.3% in both study arms; HR 0.94; 95% CI
0.57–1.56) or all-cause death (control 2.8%, EPA-group 3.1%;
HR 1.09; 95% CI 0.92–1.28). Compared to the GISSI Preven-
zione Trial death rates and especially the rates of SCD were
very low in both groups and therefore may be difﬁcult to be
reduced further by any intervention (rates for SCD: JELIS 0.2%
in both groups; GISSI 2.2%/2.9% Ω-3 versus control; GISSI-
Prevenzione Investigators, 1999). Furthermore, these low event
ratesmay at least in part be the result of a highﬁsh consumption
of the Japanese population at baseline. As most risk reduc-
tion already occurs at about 250mg EPA/DHA intake per day
(Mozaffarian andRimm,2006), a further increase ofΩ-3 intake
may not have a substantial additional effect on cardiac death
reduction (Mozaffarian, 2007).
4. In the Alpha-Omega-Study, a multicenter, double-blind,
placebo-controlled trial, 4,837 patients in the chronic stable
phase after myocardial infarction (average 3.7 years after AMI)
and60–80 years of age (21.8%women)were randomly assigned
to one of four trial arms. Margarine was used in all trial arms,
supplemented with either EPA/DHA (daily intake aimed to
be 400mg), alpha-linolenic acid (ALA, daily intake aimed to
be 2 g), EPA/DHA+ALA, or placebo, respectively (Kromhout
et al., 2010). After a follow-up of 40months, 13.9% of the
patients had a major cardiovascular event (death, non-fatal
cardiovascular events, or cardiac intervention). The rates of
the primary endpoint did not differ between the study groups.
In addition, in all secondary endpoints, including ventricular-
arrhythmia and total death, there was no signiﬁcant difference
between the study groups. Importantly, a high percentage of the
patients received“state of the artmedication,” including statins.
In a post hoc analysis after unblinding of the data in the sub-
group of patients with diabetes ventricular-arrhythmia-related
events tended to be reduced in the EPA/DHA group (HR 0.51;
95% CI 0.24–1.11) and signiﬁcantly were reduced in the ALA
group (HR 0.39; 95% CI 0.17–0.88). In a secondary analysis
of the Alpha-Omega Trial taking high risk patients with previ-
ous myocardial infarction and diabetes the EPA/DHA+ALA
group experienced signiﬁcantly less ventricular-arrhythmia-
related events (HR 0.16; 95% CI 0.04–0.69; Kromhout et al.,
2011). These differential results support the necessity to exactly
deﬁne the clinical conditions under which supplementation of
Ω-3 may be beneﬁcial.
5. In the OMEGA trial the effect of supplementation with 1 g/day
of esteriﬁed EPA/DHA on the rate of SCD and other clini-
cal events within 1 year after AMI was tested in 3,851 patients
(25.6% female, mean age 64.0 years; Rauch et al., 2006, 2010).
A 1-year follow-up was chosen, as the risk of cardiac death
after AMI including a presumed arrhythmic death is highest
in the ﬁrst 3months after the event (Solomon et al., 2005;
Pouleur et al., 2010). Furthermore, in the GISSI trial, the sig-
niﬁcance in lowering SCD by Ω-3 had already been reached
within 120 days (Marchioli et al., 2002). Following guidelines
for the management of AMI and secondary prevention 77% of
the patients in the OMEGA trial received acute percutaneous
coronary intervention, and/or thrombolysis (8.3%).At hospital
discharge the following medications were prescribed for almost
all patients: beta-blockers (94%), ACE-inhibitors (83%), ARBs
(8%), statins (94%), acetylsalicylic acid (95%), and clopidogrel
(88%). Under these conditions, the rates of SCD were 1.5%
in both study groups (OR 0.95; 95% CI 0.56–1.60) and total
mortality was 4.6% in the Ω-3 group and 3.7% in the control
group (OR 1.25; 95% CI 0.90–1.72). In none of the prede-
ﬁned secondary endpoints, including total death,major adverse
cardiovascular and cerebrovascular events, and revasculariza-
tion procedures in survivors, was found a signiﬁcant difference
between the study groups, and not even a trend in favor of the
Ω-3 group could be observed. In addition, ICD-terminatedVT
orVF in survivors was 0.1% (n = 2/1,654) in the control group
but 0.5% (n = 9/1,705) in the Ω-3 group [p = 0.06; OR (95%
CI): 4.47 (0.97–20.74)]. Furthermore, there was no signiﬁcant
difference between the study groups with regard to SCD or
total death in any of the predeﬁned subgroups of patients with
higher risk (diabetes, age >70 years, no acute revascularization,
ejection fraction <35%).
Despite these apparently homogeneous results their inter-
pretation is limited as the case estimate in the OMEGA-study
was based on anoverestimationof the rate of SCD in the control
group, thereby leading to an underpowering of the study.
6. Two other randomized controlled trials published recently also
failed to show a clear beneﬁcial effect of Ω-3 supplementa-
tion. In 563 elderly Norwegian men at high cardiovascular
risk a non-signiﬁcant tendency to a reduced all-cause mortality
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could be observed (HR 0.53; 95% CI 0.27–1.04), but the rate of
cardiovascular events remained unchanged (HR 0.89; 95% CI
0.55–1.45, follow-up 3 years; Einvik et al., 2010).
In 2,501 patients with a history of myocardial infarc-
tion, unstable angina or ischemic stroke supplementation with
EPA/DHA was not associated with a signiﬁcant decrease of
major vascular events during a follow-up of 4.7 years (HR 1.08;
95% CI 0.79–1.47; Galan et al., 2010).
Which conclusions may be drawn from the clinical studies
and the animal studies discussed above?
a. The effect of Ω-3 supplementation may depend on the
background diet and the pre-existent intake of ﬁsh oil
(Mozaffarian and Rimm, 2006; Reiffel and McDonald, 2006;
Mozaffarian, 2007).
b. With regard to earlier studies, treatment of patients with
coronary artery disease, especially treatment of patientswith
myocardial infarction has improved markedly. In the GISSI
trial (inclusion period October 1993 to September 1995)
only 4.4% of the patients had acute coronary revasculariza-
tion at baseline, and only 4.7% were on cholesterol-lowering
drugs at hospital discharge, increasing to only 46% after
42months of follow-up (GISSI-Prevenzione Investigators,
1999). Furthermore, only 43.9% of the patients included in
the GISSI trial were on beta-blocker treatment at the start
of the study, and this percentage decreased during follow-
up. It therefore may be speculated that up-to-date guideline
adjusted treatment of AMI (including acute revasculariza-
tion, medical treatment, and support of life style changes)
may interfere with molecular and cellular Ω-3 interactions
thereby weakening or competing with a potential beneﬁcial
Ω-3 effect. Although the available data not homogeneously
support this hypothesis (Marchioli et al., 2007), this aspect
should strongly be considered in future research.
c. The anti-arrhythmic effect of Ω-3 may depend on the
pathophysiological conditions that facilitate arrhythmias.
The clinical and experimental data outlined above suggest
that Ω-3 supplementation may especially protect against
ischemia-induced arrhythmias. Therefore, prevention of
ischemia by modern treatments (i.e., revascularization,
beta-blockers, statins, ACE-inhibitors, inhibition of throm-
bocyte aggregation, physical exercise) could attenuate a
potentially beneﬁcial effect of Ω-3. Beta-blockers are well
known to prevent sudden death, and even statins could
have some anti-arrhythmic effects (Anh and Marine, 2004;
Lorenz et al., 2005).
d. Potential anti-arrhythmic effects ofΩ-3 by augmentation of
vagal activity (Mozaffarian et al., 2005; O’Keefe et al., 2006)
may be blunted by beta-blocker treatment and increased
physical training during cardiac rehabilitation (Nolan et al.,
2008; Billman, 2009).
In summary, the anti-arrhythmic effect proven under experi-
mental conditions in animal models and suggested in the earlier
clinical studies appears to depend on the clinical conditions being
studied. These clinical conditions are determined by the type
and stage of the underlying myocardial disease and represent a
sumof various pathophysiological conditions (including ischemia,
reperfusion, ischemic preconditioning, scar tissue, inﬂammation,
congenital defects, etc.) and the effects of modern medication
including beta-blockers, ACE-inhibitors, statins, and other inter-
ventions potentially interfering with the arrhythmic risk, such as
exercise training.
These considerations may also apply to the role of Ω-3 in the
prevention of atrial ﬁbrillation. Positive results (Mozaffarian et al.,
2004, primary prevention in patients >65 years of age; Calò et al.,
2005, patients undergoing coronary artery surgery; Macchia et al.,
2008, postmyocardial infarction patients) were not conﬁrmed in
more recent studies and meta-analyses (Kowey et al., 2010; Sar-
avanan et al., 2010; Bianconi et al., 2011; Farquharson et al.,
2011; Liu et al., 2011). Still, it was demonstrated recently, that
the use of ﬁsh oil (DHA 1.5 g and EPA 0.3 g daily) resulted in a
prolongation and reduced dispersion of pulmonary venous and
left atrial effective refractory periods in patients with paroxysmal
atrial ﬁbrillation (Kumar et al., 2011). Furthermore, in patients
with persistent atrial ﬁbrillation on amiodarone and a renin–
angiotensin–aldosterone system inhibitor, taking Ω-3 (2 g/day)
improved the probability of maintaining sinus rhythm after direct
current cardioversion (Nodari et al., 2011). Similar to the preven-
tion of ventricular tachyarrhythmias, prevention of atrial ﬁbril-
lation therefore may depend on distinct clinical and pathophys-
iological conditions and concomitant medication. The ongoing
OPERA-trial, including a total of 1,516 patients scheduled for car-
diac surgery and in sinus rhythm, will give more insight into the
potential role of Ω-3 supplementation to prevent post-operative
atrial ﬁbrillation (Mozaffarian et al., 2011b).
SOME ASPECTS OF THE MOLECULAR AND CELLULAR
INTERACTIONS OFΩ-3 TO EXPLAIN HETEROGENEOUS
CLINICAL RESULTS
For understanding the seemingly heterogeneous efﬁcacy of Ω-3
supplementation in preventing tachyarrhythmias, it is important
to reﬂect on their molecular and cellular interactions as has been
delineated extensively in recent reviews (Leaf et al., 2003, 2005b;
Dhein et al., 2005; McLennan and Abeywardena, 2005; Den Rui-
jter et al., 2007; Lombardi and Terranova, 2007; Siddiqui et al.,
2008). In the following, only some aspects of potential relevance
for interpretation of the clinical data are discussed:
There are three major ways in which Ω-3 may interfere with
cellular and membrane function, thereby potentially moderating
cardiac rhythm:
a. Direct interactions ofΩ-3 with membrane bound proteins like
the fast sodium channel, the voltage-gated L-type Ca2+ chan-
nel, speciﬁc potassium channels, and the Na+/Ca++-exchanger
(Hallaq et al., 1990, 1992; Honore et al., 1994; Xiao et al.,
1995, 1997; Kang and Leaf, 1996; Leifert et al., 1999; Leaf et al.,
2003; Den Ruijter et al., 2007; Wang et al., 2010). Such interac-
tions may occur predominantly with circulatingΩ-3 when it is
delivered by acute administration and infusion.
b. Incorporation into the phospholipid bilayer, thereby potentially
changing membrane ﬂuidity, and/or forming Ω-3 rich micro-
domains, and/or interacting with internal binding sites. This
may result in a change of the function of membrane bound
proteins like ion channels, receptors and signal transduction
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systems (McMurchie et al., 1988; Croset and Kinsella, 1989;
Kinoshita et al., 1994; Grynberg et al., 1996; Leifert et al., 1999,
2000b; McLennan, 2001; Den Ruijter et al., 2007). Incorpora-
tion into the cellular membranes predominantly is achieved by
dietary long-term administration of Ω-3.
c. Interaction with intracellular pathways including gene expres-
sion and metabolism of phosphoinositides (Judé et al., 2006).
Circulating Ω-3 compounds are likely to have different elec-
trophysiological effects, compared to Ω-3 incorporated into the
membranes (DenRuijter et al., 2007 for review). For example,peak
cardiac sodium current was reduced by 51% after acute adminis-
tration of EPA and DHA in neonatal rat cardiomyocytes (Xiao
et al., 1995), but remained unaffected by Ω-3 incorporated in
pig and rat cardiomyocytes (Leifert et al., 2000a; Verkerk et al.,
2006). Differential effects of circulating versus incorporated Ω-3
have also been demonstrated with respect to various potassium
channels and the regulation of calcium homeostasis (Den Rui-
jter et al., 2007 for review). Incorporated Ω-3, however, also may
prevent further action potential (AP) shortening induced by circu-
latingΩ-3. Patients with high levels of incorporatedΩ-3 therefore
may not have a further beneﬁt from short term Ω-3 supple-
mentation (Den Ruijter et al., 2010). This could be of a direct
clinical relevance, as acute Ω-3 supplementation may be used
for prevention of atrial ﬁbrillation induced by cardiac surgery,
which is being investigated in the OPERA-trial (Mozaffarian et al.,
2011b).
Apart from these considerations the molecular interactions of
Ω-3 and their effects on cardiac rhythm may be inﬂuenced by a
large variety of additional conditions:
a. The various kinds ofΩ-3 formulations being used (re-esteriﬁed
triacylglycerides, ethyl-esters or phospholipids; Neubronner
et al., 2011; Schuchardt et al., 2011).
b. The activity state of membrane bound proteins and ligand
occupation of speciﬁc receptors involved in signal transduc-
tion (Rauch et al., 1989; Xiao et al., 1998; Den Ruijter et al.,
2007), or the increased responsiveness of inhibitory G-proteins
after ischemic preconditioning (Niroomand et al., 1995).
c. The activity of cellular phospholipases and the presence of
lysophosphatides that change phospholipid environment and
function of membrane bound proteins (Chien et al., 1981; Corr
et al., 1984; Rauch et al., 1994), and may even vary between dif-
ferent myocardial regions depending on the degree of ischemia
and/or inﬂammation.
d. The heterogeneity of electrical stability of myocardial cells in
the diseased heart muscle due to regional differences with
regard to various degrees of ischemia and tissue damage,
ischemic preconditioning, etc. (Dhein et al., 2005). In this
respect it should also be remembered, that in patients with
coronary artery disease, myocardium is not presenting as a
homogeneous and healthy tissue experiencing acute ischemia
in a well-deﬁned area, but rather as a mixture of healthy
myocardium, hypertrophied tissue, scar tissue, and ischemic
myocardium and includes areas of tissue with ischemic pre-
conditioning, inﬂammation, various degrees of membrane
phospholipid degradation and with more or less acute or
chronic stretch, etc. (Janse et al., 2003).
e. The species (human, various animals) being studied. The char-
acteristics of APs vary signiﬁcantly between human and various
animal myocardial cells and with gender (Karagueuzian et al.,
1982; Shattock andBers,1989;Cheng,2006;Tanaka et al., 2008).
f. The various mechanisms that trigger VT and VF. Under clini-
cal conditions VT or VF are predominantly caused by triggered
activity or by re-entrymechanisms. Fish oil shortens cardiacAP
and accentuates the AP notch, which may lead to depression or
even loss of the AP dome (Verkerk et al., 2006, 2007). Under
clinical conditions where the AP is prolonged triggered activity
may be the predominant pro-arrhythmic mechanism, which
could be inhibited in isolated cardiomyocytes from rabbits and
from patients with end stage heart failure by superfusion with
Ω-3 (Den Ruijter et al., 2008). Triggered activity also could be
inhibited in pig cardiomyocytes (Den Ruijter et al., 2006). In
keeping with these experimental results Ω-3 were effective in
reducing the arrhythmic risk in patients with idiopathic dilated
cardiomyopathy (Nodari et al., 2009).
Conversely, AP shortening also may be pro-arrhythmic by
reducing the refractory period and thereby promoting re-entry.
Supplementation with Ω-3 may increase a preexisting hetero-
geneity inAP duration and repolarization (Verkerk et al., 2007),
as can be seen, for example, in acute ischemia (Yan et al., 2004).
In this way the occurrence of unidirectional block and re-entry
may be facilitated (Janse andWit, 1989). In the clinical situation
therefore supplementation with Ω-3 may prevent or facilitate
ventricular tachyarrhythmias depending on the predominant
underlying arrhythmic mechanism (Den Ruijter et al., 2007).
Based on these considerations it becomes apparent that Ω-
3 do not have a speciﬁc way to act, but rather possess multiple
sites of potential actions, that may be inﬂuenced by a number
of external conditions at the cellular and molecular level. Mul-
tiple sites of interaction between Ω-3 and myocardial tissue in
combination with various possible ways of interference with these
biochemical interactions are unlikely to result in an unequivo-
cally predictable and homogeneous beneﬁcial effect on clinical
outcomes.
CONCLUDING REMARKS
Ω-3 clearly interfere with the physiology of myocardial cell mem-
branes through a variety of speciﬁc and unspeciﬁc pathways, and
thereby exhibit anti-arrhythmic effects under certain well-deﬁned
experimental and clinical conditions. However, these membrane
effects of Ω-3 are complex. This complexity makes it difﬁcult to
predict the effects of Ω-3 supplementation on cardiac rhythm
within the wide variety of conditions that represent clinical prac-
tice. For the future it will be necessary to deﬁne exactly the clinical
conditions in which supplementation with of Ω-3 is beneﬁcial,
and without potentially harmful effects.
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